Lotte S Spekhorst (L S Spekhorst)

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 4

Top Topics

End Stage Renal Disease

Atopic Dermatitis

Ejection Fraction

Peritoneal Dialysis

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Lotte S Spekhorst, Lisa P van der Rijst, Marlies de Graaf, Maxime van Megen, Nicolaas P A Zuithoff, André C Knulst, Marjolein de Bruin-Weller, Thuy-My Le
Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy (2022)
Lotte S Spekhorst, Daphne S Bakker, Julia Drylewicz, Theo Rispens, Floris Loeff, Celeste M Boesjes, Judith L Thijs, Geertruida L E Romeijn, Laura Loman, Marie-Louise Schuttelaar, Femke van Wijk, Marlies de Graaf, Marjolein de Bruin-Weller
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Allergy 77 (11) (2022)
Lotte S Spekhorst, Lieneke F M Ariëns, Jorien van der Schaft, Daphne S Bakker, Marijke Kamsteeg, Albert J Oosting, Ilona de Ridder, Annemiek Sloeserwij, Geertruida L E Romeijn, Marlies de Graaf, Inge Haeck, Judith L Thijs, Marie L A Schuttelaar, Marjolein de Bruin-Weller
Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry. Allergy 75 (9) (2020)
Lotte S Spekhorst, J M P A van den Reek, A C Knulst, Heike Röckmann
Determinants of omalizumab drug survival in a long-term daily practice cohort of patients with chronic urticaria. Allergy 74 (6) (2019)